Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 4/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL705943 | 0.92 | KCNH2 (0.46) | KCNH2POLBCHRM1TP53NPC1 | |
| SCHEMBL709161 | 0.88 | KCNH2 (0.51) | KCNH2POLBCHRM1ALDH1A1 | |
| SCHEMBL705652 | 0.87 | TSHR (0.53) | POLBCHRM1TP53KMT2AGAA | |
| SCHEMBL707302 | 0.86 | KMO (0.56) | KCNH2CHRM1KMT2ATHRB | |
| SCHEMBL708589 | 0.86 | KCNH2 (0.51) | KCNH2CHRM1ALDH1A1 | |
| SCHEMBL707115 | 0.86 | KCNH2 (0.56) | KCNH2CHRM1ALDH1A1 | |
| SCHEMBL708216 | 0.85 | KCNH2 (0.54) | KCNH2POLBCHRM1NPC1RXFP1 | |
| SCHEMBL708406 | 0.85 | KCNH2 (0.55) | KCNH2CHRM1KMT2AALDH1A1 | |
| SCHEMBL704650 | 0.84 | CHRM1 (0.60) | KCNH2CHRM1ALDH1A1 | |
| SCHEMBL705187 | 0.84 | KCNH2 (0.53) | KCNH2POLBCHRM1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124602-B2 | Compounds for the treatment of multi-drug resistant bacterial infections | ASTRAZENECA AB (SE) | 2012-02-28 | — | — | US | disclosed |
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092495-A1 | COMPOUNDS FOR THE TREATMENT OF MULTI-DRUG RESISTANT BACTERIAL INFECTIONS | PIGS, BPGM, IPMK | KCNH2 4242/4885POLB 449/4885CHRM1 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.